Metoprolol Tartrate Global Market Report 2024

Metoprolol tartrate is a beta-blocker medication primarily prescribed for managing conditions such as high blood pressure, angina (chest pain), heart failure, and as part of treatment following a heart attack. It functions by blocking the effects of natural chemicals such as epinephrine on the heart and blood vessels, thereby reducing blood pressure, heart rate, and cardiac strain. Additionally, metoprolol tartrate is used to prevent migraine headaches.

The medication is available for administration through oral and injectable routes. Oral metoprolol tartrate refers to formulations taken by mouth, typically in tablet or capsule form, and is utilized in treating hypertension, cardiovascular issues, and other medical conditions. Distribution channels for metoprolol tartrate include hospital pharmacies, retail pharmacies, and online pharmacies.

The metoprolol tartrate market research report is one of a series of new reports that provides metoprolol tartrate market statistics, including the metoprolol tartrate industry global market size, regional shares, competitors with metoprolol tartrate market share, detailed metoprolol tartrate market segments, market trends, and opportunities, and any further data you may need to thrive in the metoprolol tartrate industry. These metoprolol tartrate market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metoprolol tartrate market size has grown strongly in recent years. It will grow from $6.1 billion in 2023 to $6.41 billion in 2024 at a compound annual growth rate (CAGR) of 5%. The growth observed in the historic period can be attributed to several factors, increasing awareness about hypertension, advancements and expansions in healthcare systems, early patent protections for medications such as metoprolol tartrate, and various health initiatives aimed at improving cardiovascular health.

The metoprolol tartrate market size is expected to see strong growth in the next few years. It will grow to $7.83 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The anticipated growth in the forecast period can be attributed to several factors, the advancement of personalized medicine, improved medical education and training focused on cardiovascular disease management, the establishment of efficient drug distribution networks, patient education initiatives, and increased funding for cardiovascular research. Major trends expected in the forecast period include the analysis of consumer behavior, optimization of supply chains, the development of 3D printing technologies for customizable drug formulations, and the rising development and utilization of mobile health applications.

The growth of the metoprolol tartrate market is expected to be driven by the rising prevalence of hypertension. Hypertension, a complex condition influenced by lifestyle, genetics, and underlying health issues, can develop gradually and is exacerbated by factors such as poor diet, lack of exercise, obesity, stress, and an aging population. Metoprolol tartrate manages hypertension by reducing heart rate and cardiac output, thereby lowering blood pressure. For example, the Australian Bureau of Statistics reported in December 2023 that 11.6% of the population, or approximately 3 million people, had hypertension in 2022. Additionally, according to a joint press release by the World Health Organization and Imperial College London in August 2021, the number of adults aged 30-79 with hypertension globally increased from 650 million to 1.28 billion over the past three decades, highlighting the significant driver behind the metoprolol tartrate market's growth.

The increasing prevalence of coronary heart disease is anticipated to contribute to the expansion of the metoprolol tartrate market. This condition involves the narrowing of the heart's blood vessels due to plaque buildup, leading to reduced blood flow and potential cardiac issues such as angina and heart attacks. Sedentary lifestyles, unhealthy diets, smoking, obesity, high blood pressure, and diabetes are key contributors to coronary heart disease. Metoprolol tartrate effectively manages this condition by lowering heart rate and blood pressure, thereby preventing angina, protecting against acute coronary events, improving long-term outcomes, and managing arrhythmias. For instance, the Australian Bureau of Statistics indicated that in 2020-21, approximately 571,000 Australians aged 18 and over (2.9% of the adult population) were living with coronary heart disease, with prevalence notably increasing among those aged 75 and over, affecting approximately 11% of this age group.

Leading companies in the metoprolol tartrate market are focusing on developing generic equivalents to offer cost-effective alternatives to branded medications for treating hypertension and cardiovascular conditions. These bioequivalent products provide the same therapeutic effects as their branded counterparts, ensuring similar absorption rates into the bloodstream. For example, Lupin Pharmaceuticals received approval from the FDA in August 2023 to market a generic equivalent of Toprol-XL Tablets, expanding their range of generic cardiovascular treatments in the U.S. market. This strategic approach aims to meet diverse patient needs with various tablet strengths indicated for hypertension and angina pectoris treatment.

Major companies operating in the metoprolol tartrate market are Pfizer Inc., AstraZeneca plc, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Aurobindo Pharma, Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, Glenmark Pharmaceuticals Ltd., Emcure Pharmaceuticals Ltd., Alembic Pharmaceuticals Inc., Accord Healthcare Inc., Beximco Pharmaceuticals Ltd., Micro Labs Ltd., Inventia Healthcare Pvt. Ltd., Watson Laboratories Inc., Aizant Drug Research Solutions Pvt. Ltd., Zydus Cadila, Validus Pharmaceuticals LLC, Strides Pharma Science Limited, APO-MEDIX Pty Ltd.

North America was the largest region in the metoprolol tartrate market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metoprolol tartrate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the metoprolol tartrate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metoprolol tartrate market consists of sales of extended-release tablets, lopressor, and intravenous formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.